Treatment with Esbriet (pirfenidone) or Ofev (nintedanib) significantly slowed the progression of idiopathic pulmonary fibrosis (IPF) in a real-life clinical setting, an Italian study reported. The study, “Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre” was published in the journal…
Samumed and United Therapeutics announced an exclusive license agreement for North American rights to Samumed’s investigational therapy SM04646 to treat idiopathic pulmonary fibrosis (IPF). Under the agreement, United Therapeutics will pay Samumed $10 million up-front, plus up to $340 million in developmental milestones in addition to other…
Corbus Pharmaceuticals has acquired from Jenrin Discovery more than 600 compounds designed to target the endocannabinoid system, including CRB-4001 for the treatment of fibrotic diseases affecting the lungs, liver, heart, and kidney. The endocannabinoid system is associated with the resolution (or shutting off) of the inflammatory response, which…
Roivant Sciences has launched a new company whose focus is developing potential treatments for serious respiratory diseases. Named Respivant Sciences, it will begin by advancing RVT-1601 as an investigative therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). RVT-1601, formerly known as PA101, is a novel formulation…
More than 700 medical experts, pharmaceutical executives, patient advocates, and others are expected to converge on Washington, D.C., next month for the 2018 NORD Rare Diseases & Orphan Products Breakthrough Summit. The Oct. 15-16 event, sponsored by the National Organization for Rare Diseases (NORD), takes place at the…
Long-term treatment with Ofev (nintedanib) can safely slow disease progression in people with idiopathic pulmonary fibrosis (IPF), new four-year data from INPULSIS-ON, an open-label Phase 3 extension trial, show. The findings were reported in “Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from…
Treatment of idiopathic pulmonary fibrosis (IPF) with Esbriet (pirfenidone) leads to stable lung function over two years, according to a real-world study. The data matches previous results from Phase 3 trials. The research, “Functional decline over time in patients with IPF treated with pirfenidone: the…
A comprehensive Swedish study reveals low use and lack of persistence with Esbriet (pirfenidone) treatment among patients with pulmonary fibrosis (PF). Results of this real-world study were presented in a poster titled “Pirfenidone Use in a Swedish Cohort of Patients With Pulmonary Fibrosis” during the…
The National Institutes of Health (NIH) has granted $12 million to researchers at Cedars-Sinai Medical Center to continue studying two lung diseases — idiopathic pulmonary fibrosis and chronic lung allograft dysfunction. Idiopathic pulmonary fibrosis (IPF) is characterized by progressive scarring of lung tissue which leads to difficulty breathing. Chronic lung allograft dysfunction is a complication…
FibroGen’s investigational compound pamrevlumab has received fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF). The agency’s decision follows review of the double-blind PRAISE Phase 2b study (NCT01890265) results, which showed that, over 48 weeks, intravenous…
Get regular updates to your inbox.
